224 related articles for article (PubMed ID: 19519686)
1. Survival of patients with pseudomyxoma peritonei treated by serial debulking.
Järvinen P; Järvinen HJ; Lepistö A
Colorectal Dis; 2010 Sep; 12(9):868-72. PubMed ID: 19519686
[TBL] [Abstract][Full Text] [Related]
2. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
[TBL] [Abstract][Full Text] [Related]
3. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
[TBL] [Abstract][Full Text] [Related]
4. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Smeenk RM; Verwaal VJ; Antonini N; Zoetmulder FA
Ann Surg; 2007 Jan; 245(1):104-9. PubMed ID: 17197972
[TBL] [Abstract][Full Text] [Related]
5. Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin.
Youssef H; Newman C; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
Dis Colon Rectum; 2011 Mar; 54(3):293-9. PubMed ID: 21304299
[TBL] [Abstract][Full Text] [Related]
6. Commentary on 'Survival of patients with pseudomyxoma peritonei treated by serial debulking'.
Moran BJ
Colorectal Dis; 2010 Sep; 12(9):872-3. PubMed ID: 20718839
[No Abstract] [Full Text] [Related]
7. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.
Sugarbaker PH
Eur J Surg Oncol; 2001 Apr; 27(3):239-43. PubMed ID: 11373099
[TBL] [Abstract][Full Text] [Related]
8. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study.
Smeenk RM; van Velthuysen ML; Verwaal VJ; Zoetmulder FA
Eur J Surg Oncol; 2008 Feb; 34(2):196-201. PubMed ID: 17524597
[TBL] [Abstract][Full Text] [Related]
9. Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second-look operation.
Yan H; Pestieau SR; Shmookler BM; Sugarbaker PH
Mod Pathol; 2001 Mar; 14(3):164-71. PubMed ID: 11266521
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal hyperthermia in the management of pseudomyxoma peritonei.
Hsu KH; Chou CY; Chang YC
Hepatogastroenterology; 2007; 54(73):47-52. PubMed ID: 17419229
[TBL] [Abstract][Full Text] [Related]
11. [Pseudomyxoma peritonei; a rare tumour that can be treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].
Smeenk RM; Verwaal VJ; Zoetmulder FA
Ned Tijdschr Geneeskd; 2007 Feb; 151(7):418-23. PubMed ID: 17343142
[TBL] [Abstract][Full Text] [Related]
12. Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved.
Dayal S; Taflampas P; Riss S; Chandrakumaran K; Cecil TD; Mohamed F; Moran BJ
Dis Colon Rectum; 2013 Dec; 56(12):1366-72. PubMed ID: 24201390
[TBL] [Abstract][Full Text] [Related]
13. Outcome differences between debulking surgery and cytoreductive surgery in patients with Pseudomyxoma peritonei.
Andréasson H; Graf W; Nygren P; Glimelius B; Mahteme H
Eur J Surg Oncol; 2012 Oct; 38(10):962-8. PubMed ID: 22809859
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
[TBL] [Abstract][Full Text] [Related]
15. [Pseudomyxoma peritonei--a syndrome with varying prognosis].
Mahteme H; Graf W
Lakartidningen; 2003 Sep; 100(38):2936-40. PubMed ID: 14558213
[TBL] [Abstract][Full Text] [Related]
16. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
Baratti D; Kusamura S; Nonaka D; Cabras AD; Laterza B; Deraco M
Ann Surg; 2009 Feb; 249(2):243-9. PubMed ID: 19212177
[TBL] [Abstract][Full Text] [Related]
17. [Pseudomyxoma peritonei].
Dejong CH; Booster MH; Theunissen PH; Beets GL; van Duin CJ
Ned Tijdschr Geneeskd; 1997 Jun; 141(24):1196-8. PubMed ID: 9380155
[TBL] [Abstract][Full Text] [Related]
18. Secondary cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudomyxoma peritonei: a study of timing and the impact of malignant dedifferentiation.
Chua TC; Al-Zahrani A; Saxena A; Liauw W; Zhao J; Morris DL
J Am Coll Surg; 2010 Oct; 211(4):526-35. PubMed ID: 20729102
[TBL] [Abstract][Full Text] [Related]
19. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
20. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy.
Elias D; Gilly F; Quenet F; Bereder JM; Sidéris L; Mansvelt B; Lorimier G; Glehen O;
Eur J Surg Oncol; 2010 May; 36(5):456-62. PubMed ID: 20227231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
